InvestorsObserver
×
News Home

Should You Sell eFFECTOR Therapeutics Inc (EFTR) in Biotechnology Industry?

Tuesday, November 21, 2023 01:53 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Sell eFFECTOR Therapeutics Inc (EFTR) in Biotechnology Industry?

eFFECTOR Therapeutics Inc (EFTR) is near the top in its industry group according to InvestorsObserver. EFTR gets an overall rating of 58. That means it scores higher than 58 percent of stocks. eFFECTOR Therapeutics Inc gets a 75 rank in the Biotechnology industry. Biotechnology is number 49 out of 148 industries.

Overall Score - 58
EFTR has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on EFTR!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With eFFECTOR Therapeutics Inc Stock Today?

eFFECTOR Therapeutics Inc (EFTR) stock is up 8.53% while the S&P 500 has fallen -0.16% as of 1:49 PM on Tuesday, Nov 21. EFTR has risen $0.05 from the previous closing price of $0.59 on volume of 4,535,530 shares. Over the past year the S&P 500 is higher by 14.94% while EFTR has risen 28.00%. EFTR lost -$0.77 per share the over the last 12 months. Click Here to get the full Stock Report for eFFECTOR Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App